Sonoma Pharmaceuticals, Inc. (SNOA) stock
Close on Nov 12, 2026Market cap $5.60MP/E –Yield –
Sonoma Pharmaceuticals, Inc. grew revenue 38.7% to $23.49M over the twelve months to Sep 30, 2026. Free cash flow was -$2.79M. At the latest close the market valued the company at $5.60M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $5.60M
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- 0.85
- Dividend yield
- –
- Free cash flow yield
- -49.76%
Fundamentals
- Revenue
- $23.49M
- Net income
- -$1.80M
- EPS, diluted
- -$0.91
- Free cash flow
- -$2.79M
- Book value per share
- $1.35
- Diluted shares
- 5M
Trading
- Previous close
- $1.24
- Open
- $1.26
- Day's range
- $1.15 – $1.27
- Volume
- 157,745
- Average volume (20 days)
- 61,650
- Beta (5 years)
- 1.94
- 52-week range
- $0.85 – $3.95
- RSI (14 days)
- 51.0
- Volatility (1 year)
- 72.8%
- Relative volume
- 1.68×
- WACC
- 14.5%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SNOA | S&P 500 | Difference | SNOA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.9% | -2.7% | −2.2 pts | ||
| 3 months | -14.6% | -1.7% | −12.9 pts | ||
| Year to date | -67.9% | +11.9% | −79.8 pts | ||
| 1 year | -68.2% | +12.0% | −80.2 pts | ||
| 3 years | -58.4% | +78.2% | −136.6 pts | -25.3% | +21.2% |
| 5 years | -99.0% | +73.2% | −172.2 pts | -60.1% | +11.6% |
| 10 years | -99.9% | +309.6% | −409.5 pts | -48.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sonoma Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Sonoma Pharmaceuticals
Surgical & Medical Instruments & Apparatus
Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid products across six primary business channels: wound care, dermatology, eye care, podiatry, animal health care, and non-toxic surface disinfectants. Its offerings include prescription, over-the-counter, and office-dispense topical solutions, hydrogels, sprays, and cleansers designed to alleviate pain, itch, redness, and scarring while supporting skin and wound healing. The company distributes its medical device solutions directly and through commercial partners to hospitals, physicians, retail pharmacy chains, pet specialty stores, and everyday consumers.
Company profile, executives and historySonoma Pharmaceuticals stock: common questions
What is Sonoma Pharmaceuticals's stock price?
SNOA closed at $1.17 on Nov 12, 2026, down 5.65% on the day. Over the past 52 weeks it traded between $0.85 and $3.95.
What is Sonoma Pharmaceuticals's market cap?
Sonoma Pharmaceuticals was worth $5.60M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SNOA's P/E ratio?
Sonoma Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.91), so it has no meaningful P/E ratio.
How much revenue does Sonoma Pharmaceuticals make?
Sonoma Pharmaceuticals reported revenue of $23.49M for the twelve months to Sep 30, 2026, up 38.7% from a year earlier.
Does Sonoma Pharmaceuticals pay a dividend?
No. Sonoma Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has SNOA stock performed over the past year?
Including dividends, SNOA returned -68.2% over the past year, against +12.0% for the S&P 500.
How many SNOA shares are sold short?
0M shares were sold short at the latest FINRA report, 1.57% of the float, or 1.7 days of average trading volume.
Who are Sonoma Pharmaceuticals's competitors?
Companies most similar to Sonoma Pharmaceuticals by business, industry and size include BDMD, SRTS, KRMD, UTMD, DRIO.
See a number that looks wrong?